Cannabidiol and Prolonged Exposure
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- San Diego, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 144 people enrolled
- Started
- 1 Oct 2019
- Ended
- 30 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Prolonged Exposure
- Cannabidiol
- placebo
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Over the age of 18 at the time of screening
- Judged by the study physician to be in generally good health
- Meet clinical criteria for Posttraumatic Stress Disorder (PTSD) on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
- Negative urine pregnancy test
Who cannot take part
- Patient is currently prescribed medications with possible CBD-drug interactions
- Positive drug screen for THC, barbiturates, amphetamines (if not prescribed), benzodiazepines, and/or opiates
- History of significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to cannabinoids
- Current or past DSM-5 diagnosis of dissociative identity disorder, eating disorder with active purging, personality disorders, primary psychotic disorder, or bipolar affective disorder type 1
- History of actual suicide attempt in the last 5 years
- History of treatment for, or evidence of, moderate to severe alcohol or drug abuse within the past year or regular alcohol consumption exceeding recommended limits
- Lifetime history of Cannabis Use Disorder
- Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening
- Patient has had a change in psychopharmacotherapy regimen in the last 4 weeks, or has any plans to change regimen over the course of the study
- Patient is engaged in trauma-related psychotherapy for PTSD
- Unmanaged obstructive sleep apnea
- Pregnant or breastfeeding
Where in United States
- VA San Diego Healthcare System, San Diego, CASan Diego, United States
About the trial
What the trial wants to find out
The trial will include a randomized control trial to evaluate the efficacy of using Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure therapy (PE). The trial will compare PE + CBD to PE + placebo in a sample of 136 military Veterans with PTSD at the VA San Diego Medical Center. The study represents the logical and innovative next step for augmenting existing treatments and developing novel pharmacotherapy for PTSD. Findings from the proposed RCT will inform clinical practice and policy by investigating whether administration of CBD in the context of PE therapy will improve treatment outcomes for military Veterans with PTSD.
The 2 groups in the trial
- Prolonged Exposure + CannabidiolTreatment being tested
Psychotherapy plus active medication
Treatment: Prolonged Exposure and Cannabidiol
- Prolonged Exposure + PlaceboExisting treatment, for comparison
Psychotherapy plus placebo medication
Treatment: Prolonged Exposure and placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cannabidiol as an Adjunctive to Prolonged Exposure for the Treatment of PTSD
- Record updated
- 17 November 2026